Limits...
The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer.

Huang HP, Feng H, Qiao HB, Ren ZX, Zhu GD - Onco Targets Ther (2015)

Bottom Line: Fibroblast growth factor receptor 4 (FGFR4) has been proved to be correlated with progression and prognosis in many cancers.Moreover, we evaluated the prognostic value of FGFR4 by Kaplan-Meier survival curve and Cox regression model.FGFR4 expression was significantly associated with tumor diameter (P=0.039).

View Article: PubMed Central - PubMed

Affiliation: Department of General Medicine, Linyi Hospital Affiliated to Shandong University, Linyi City, People's Republic of China.

ABSTRACT

Background: Fibroblast growth factor receptor 4 (FGFR4) has been proved to be correlated with progression and prognosis in many cancers. However, the significance of FGFR4 in non-small-cell lung cancer (NSCLC) is still not well elucidated.

Methods: In our experiment, we detected FGFR4 expression in 237 samples of NSCLC with immunohistochemistry, and further analyzed the correlation between FGFR4 and clinicopathologic features of NSCLC with chi-square test. Moreover, we evaluated the prognostic value of FGFR4 by Kaplan-Meier survival curve and Cox regression model. By regulating the expression of FGFR4 by overexpression or knockdown, we assessed the role of FGFR4 on NSCLC cell proliferation.

Results: FGFR4 expression was high in NSCLC (46.8%, 111/237). FGFR4 expression was significantly associated with tumor diameter (P=0.039). With univariate (P=0.009) and multivariate (P=0.002) analysis, FGFR4 was identified as an independent prognostic factor in NSCLC (P=0.009). Moreover, FGFR4 can promote the proliferation of NSCLC cell lines.

Conclusion: FGFR4 is an independent prognostic biomarker in NSCLC. FGFR4 can accelerate the proliferation of NSCLC cell lines, indicating FGFR4 could be a potential drug target of NSCLC.

No MeSH data available.


Related in: MedlinePlus

Correlations between overall survival rate and FGFR4 expression and lymph invasion status.Notes: Higher FGFR4 expression (A) and positive lymphatic invasion (B) can predict unfavorable prognosis of serous ovarian cancer.Abbreviation: FGFR4, fibroblast growth factor receptor 4.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4447177&req=5

f2-ott-8-1157: Correlations between overall survival rate and FGFR4 expression and lymph invasion status.Notes: Higher FGFR4 expression (A) and positive lymphatic invasion (B) can predict unfavorable prognosis of serous ovarian cancer.Abbreviation: FGFR4, fibroblast growth factor receptor 4.

Mentions: To evaluate the prognostic value of FGFR4 in NSCLC, we first analyzed the correlation between FGFR4 expression and the 5-year overall survival rate with univariate analysis (Table 3). With the Kaplan–Meier method, we demonstrated that FGFR4 higher expression was correlated to poorer prognosis in NSCLC (P=0.009). In the FGFR4 higher-expression group, the 5-year overall survival rate was 17.4% with average survival time 39.8 months, while in the lower-expression group, the 5-year overall survival rate was 54.8% with average survival time 62.1 months (Figure 2A). In addition, stage of lymph node metastasis was also defined as a prognostic factor in NSCLC (P=0.003). Positive lymphatic invasion had a poorer prognosis than negative lymphatic invasion (42.7% vs 52.7% survival rate) (Figure 2B).


The prognostic significance of fibroblast growth factor receptor 4 in non-small-cell lung cancer.

Huang HP, Feng H, Qiao HB, Ren ZX, Zhu GD - Onco Targets Ther (2015)

Correlations between overall survival rate and FGFR4 expression and lymph invasion status.Notes: Higher FGFR4 expression (A) and positive lymphatic invasion (B) can predict unfavorable prognosis of serous ovarian cancer.Abbreviation: FGFR4, fibroblast growth factor receptor 4.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4447177&req=5

f2-ott-8-1157: Correlations between overall survival rate and FGFR4 expression and lymph invasion status.Notes: Higher FGFR4 expression (A) and positive lymphatic invasion (B) can predict unfavorable prognosis of serous ovarian cancer.Abbreviation: FGFR4, fibroblast growth factor receptor 4.
Mentions: To evaluate the prognostic value of FGFR4 in NSCLC, we first analyzed the correlation between FGFR4 expression and the 5-year overall survival rate with univariate analysis (Table 3). With the Kaplan–Meier method, we demonstrated that FGFR4 higher expression was correlated to poorer prognosis in NSCLC (P=0.009). In the FGFR4 higher-expression group, the 5-year overall survival rate was 17.4% with average survival time 39.8 months, while in the lower-expression group, the 5-year overall survival rate was 54.8% with average survival time 62.1 months (Figure 2A). In addition, stage of lymph node metastasis was also defined as a prognostic factor in NSCLC (P=0.003). Positive lymphatic invasion had a poorer prognosis than negative lymphatic invasion (42.7% vs 52.7% survival rate) (Figure 2B).

Bottom Line: Fibroblast growth factor receptor 4 (FGFR4) has been proved to be correlated with progression and prognosis in many cancers.Moreover, we evaluated the prognostic value of FGFR4 by Kaplan-Meier survival curve and Cox regression model.FGFR4 expression was significantly associated with tumor diameter (P=0.039).

View Article: PubMed Central - PubMed

Affiliation: Department of General Medicine, Linyi Hospital Affiliated to Shandong University, Linyi City, People's Republic of China.

ABSTRACT

Background: Fibroblast growth factor receptor 4 (FGFR4) has been proved to be correlated with progression and prognosis in many cancers. However, the significance of FGFR4 in non-small-cell lung cancer (NSCLC) is still not well elucidated.

Methods: In our experiment, we detected FGFR4 expression in 237 samples of NSCLC with immunohistochemistry, and further analyzed the correlation between FGFR4 and clinicopathologic features of NSCLC with chi-square test. Moreover, we evaluated the prognostic value of FGFR4 by Kaplan-Meier survival curve and Cox regression model. By regulating the expression of FGFR4 by overexpression or knockdown, we assessed the role of FGFR4 on NSCLC cell proliferation.

Results: FGFR4 expression was high in NSCLC (46.8%, 111/237). FGFR4 expression was significantly associated with tumor diameter (P=0.039). With univariate (P=0.009) and multivariate (P=0.002) analysis, FGFR4 was identified as an independent prognostic factor in NSCLC (P=0.009). Moreover, FGFR4 can promote the proliferation of NSCLC cell lines.

Conclusion: FGFR4 is an independent prognostic biomarker in NSCLC. FGFR4 can accelerate the proliferation of NSCLC cell lines, indicating FGFR4 could be a potential drug target of NSCLC.

No MeSH data available.


Related in: MedlinePlus